title: Implications of a positive crossmatch in liver transplantation: a 20-year review.
abstract: Whether a positive crossmatch result has any relevance to liver transplantation (LT) outcomes remains controversial. We assessed the impact of a positive crossmatch result on patient and graft survival and posttransplant complications. During a 20-year period, 2723 LT procedures with crossmatch results were identified: 2479 primary transplants and 244 retransplants. The rates of positive B cell and T cell crossmatches were 10.1% and 7.4%, respectively, for primary transplants and 14.6% and 6.4%, respectively, for retransplants (P = 0.049 for a B cell crossmatch). Across all primary transplants, females (P < 0.001) and patients with autoimmune hepatitis (P < 0.001) had greater frequencies of positive crossmatches. There was no effect from race or age. For both primary transplants and retransplants, patient survival and graft survival were not affected by the presence of a positive crossmatch. With respect to posttransplant complications, there were no differences in rejection episodes (hyperacute, acute, or chronic) or technical complications (biliary and vascular) between negative and positive crossmatch groups. However, there were significant differences in the pathological findings of preservation injury (PI) on liver biopsy samples taken at the time of transplantation and within the first week of transplantation (P = 0.003 for B cells and P = 0.03 for T cells). In summary, a positive crossmatch had no significant impact on patient survival or graft outcomes. However, there was a significantly higher incidence of PI in primary LT recipients with a positive crossmatch. This finding is important for a broader understanding of PI, which may include a significant immunological component.
authors.affiliation: Annette C and Harold C Simmons Transplant Institute, Baylor University Medical Center, Dallas, TX, USA. richarru@baylorhealth.edu
authors.forename: Richard
authors.initials: R
authors.lastname: Ruiz
authors.forename: Koji
authors.initials: K
authors.lastname: Tomiyama
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Campsen
authors.forename: Robert M
authors.initials: RM
authors.lastname: Goldstein
authors.forename: Marlon F
authors.initials: MF
authors.lastname: Levy
authors.forename: Greg J
authors.initials: GJ
authors.lastname: McKenna
authors.forename: Nicholas
authors.initials: N
authors.lastname: Onaca
authors.forename: Brian
authors.initials: B
authors.lastname: Susskind
authors.forename: Glenn W
authors.initials: GW
authors.lastname: Tillery
authors.forename: Goran B
authors.initials: GB
authors.lastname: Klintmalm
mesh_terms: D001402:B-Lymphocytes / Q000276:immunology*; D001706:Biopsy; D016009:Chi-Square Distribution; D005260:Female; D006084:Graft Rejection / Q000276:immunology* / Q000401:mortality / Q000517:prevention & control; D006085:Graft Survival; D006648:Histocompatibility; D006650:Histocompatibility Testing; D006801:Humans; D053208:Kaplan-Meier Estimate; D016031:Liver Transplantation / Q000009:adverse effects / Q000276:immunology* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D012189:Retrospective Studies; D018570:Risk Assessment; D012307:Risk Factors; D013601:T-Lymphocytes / Q000276:immunology*; D013781:Texas; D013997:Time Factors; D023001:Transplantation Tolerance; D016896:Treatment Outcome